This case illustrates that bispecific (dual) anti-CD20/CD19 CAR-T therapy can induce durable, immunosuppression-free remission in both RA and concurrent DLBCL, with an acceptable safety profile. This evidence concerns the gene CD19 and rheumatoid arthritis.